Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6363689 | 1.00 | HSD11B1 (0.64) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL6363691 | 1.00 | HSD11B1 (0.64) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL348927 | 0.94 | HSD11B1 (0.66) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL348612 | 0.94 | HSD11B1 (0.66) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL348613 | 0.94 | HSD11B1 (0.66) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL348926 | 0.94 | HSD11B1 (0.66) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL1321261 | 0.90 | HSD11B1 (0.78) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL351258 | 0.90 | HSD11B1 (0.78) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL351257 | 0.90 | HSD11B1 (0.78) | HSD11B1CYP2D6NPY5R | |
| SCHEMBL348749 | 0.90 | HSD11B1 (0.78) | HSD11B1CYP2D6NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255154-A1 | Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes | INCYTE CORPORATION (US) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255154-A1 | Cycloalkylcarbonyl-3H-spiro[2-benzofuran-1,3'-pyrrolidin]-3-ones: N-methyl-5-[4-(1-{[3-oxo-1'H,3H-spiro[2-benzofuran-1,3'-pyrrolidin]-1'-yl]carbonyl}cyclopropyl)phenyl]pyridine-2-carboxamide; 11- beta hydroxyl steroid dehydrogenase type 1 inhibitors; mineralcorticoid receptor antagonists; diabetes | HSD11B1, NR3C2, SRD5A1 | HSD11B1 1/4885CYP2D6 349/4885NPY5R 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.